CD82 and cancer: Its ability to inhibit cell motility, invasion and adhesion, together with the clinical observations that KAI1/CD82 expression is often lost/reduced in cancer, strongly suggests that KAI1/CD82 has an anti-oncogenic role in cancer [66].